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Abstract
Background: Mifepristone (RU486), a potent antagonist of progesterone and glucocorticoids, is involved in immune
regulation. Our previous studies demonstrated that mifepristone directly augments the cytotoxicity of human uterine
natural killer (uNK) cells. However, the mechanism responsible for this increase in cytotoxicity is not known. Here, we
explored whether the increased cytotoxicity in uNK cells produced by mifepristone is due to either anti-progesterone or
anti-glucocorticoid activity, and also investigated relevant changes in the mitogen-activated protein kinase (MAPK)
pathway.
Methodology/Principal Findings: Uterine NK cells were isolated from decidual samples and incubated with different
concentrations of progesterone, cortisol, or mifepristone. The cytotoxicity and perforin expression of uNK cells were
detected by mitochondrial lactate dehydrogenase-based MTS staining and flow cytometry assays, respectively.
Phosphorylation of components of the MAPK signaling pathway was detected by Western blot. Cortisol attenuated uNK
cell-mediated cytotoxicity in a concentration-dependent manner whereas progesterone had no effect. Mifepristone alone
increased the cytotoxicity and perforin expression of uNK cells; these effects were blocked by cortisol. Furthermore,
mifepristone increased the phosphorylation of ERK1/2 in a cortisol-reversible manner. Specific ERK1/2 inhibitor PD98059 or
U0126 blocked cortisol- and mifepristone-induced responses in uNK cells.
Conclusions/Significance: These results suggest that mifepristone acts as a glucocorticoid antagonist to augment uNK cell-
mediated cytotoxicity via ERK activation, which may be caused by increased perforin expression. These observations may
reveal an important mechanism by which mifepristone upregulates the cytotoxicity of uNK cells.
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Introduction
Mifepristone (RU486) is a synthetic 19-norsteroid, and a potent
antagonist of progesterone and glucocorticoids. Basic research has
demonstrated a variety of potential applications for mifepristone in
the fields of gynecology, endocrinology, oncology, and immunol-
ogy [1–5]. It has been used primarily as an anti-progesterone drug
to produce early pregnancy termination, and as an anti-
glucocorticoid drug to ameliorate the clinical manifestations of
Cushing’s syndrome [6]. Recently, several studies demonstrated
that for the purpose of contraception, low-dose mifepristone
retards endometrial development, so-called endometrial contra-
ception [7]. Therefore, mifepristone may serve as a novel,
estrogen-free, contraceptive pill with little or no change to the
menstrual cycle and few adverse side effects.
In addition to its antagonistic activities, accumulating evidence
suggests that mifepristone may be involved in modulation of the
immune response. In vitro, mifepristone significantly inhibits the
proliferation of lymphocytes [5,8] and increases the cytotoxicity of
natural killer (NK) cells from pregnant subjects [9]. Uterine NK
(uNK) cells are the most abundant lymphocytes in endometrial
and decidual tissue, characterized as brightly staining for CD56
(CD56
+) and dimly staining for CD16 (CD16
2). Important roles
have been proposed for uNK cells in immunotolerance, regulation
of trophoblast invasion, and remodeling of the spiral arteries [10].
Altered numbers of uNK cells have been associated with recurrent
miscarriage, recurrent implantation failure, fetal growth restric-
tion, and preeclampsia [11]. For terminating early pregnancy, Lu
et al. [12] demonstrated that mifepristone with misoprostol might
increase the expression of CD56
+-NK cells in decidua and induce
disorder of the decidual micro-environment, which might be one
mechanism underlying the abortifacient properties of this drug
combination. Our previous studies showed that low-dose mifep-
ristone increases the number of CD56
+-NK cells, and the
percentages of the NK cell subset CD3
2CD56
+CD16
2 in human
endometrial explants [13]. Uterine NK cell-mediated cytotoxicity
and perforin expression were also augmented by treatment with
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modulation by mifepristone in uNK cells, however, are not fully
understood.
Progesterone modulates local immune responses at the
maternal-fetal interface [15]. Recently, classical progesterone
receptor (PR) expression was demonstrated in peripheral blood
NK cells. These cells mediate the reduction of interferon (IFN)-c
secretion and the proapoptotic effects of progesterone [16].
However, human uNK cells have no PR expression [17] and
progesterone cannot directly affect the biological activity of human
uNK cells [18]. In contrast, the glucocorticoid receptor (GR) was
identified in both uterine and peripheral blood NK cells [17,19].
Quenby’s study [20] showed that 29 women with a history of
recurrent miscarriage had elevated levels of uNK cells. Oral
prednisolone suppressed uNK cells from 14 to 9% between the
first experimental biopsy before which the drug had not been
administered and the second in which it had. These results
indicated that glucocorticoid therapy has potential applications in
treatment of female reproductive disorders.
In light of their immunosuppressant activity, it has been
suggested that glucocorticoids might assist in preventing immune
rejection of the implanting embryo [21]. These results raise the
possibility that the GR is involved in the regulation of uNK cell
function. Therefore, the aim of the present study was to investigate
whether mifepristone acts as a glucocorticoid or progesterone
antagonist to modulate the cytotoxicity of uNK cells. We also
studied the role of the mitogen-activated protein kinase (MAPK)
pathway as a potential mechanism underlying the effects of
mifepristone on human uNK cells.
Materials and Methods
Tissue collection
The study was approved by the Ethics Committee of Women’s
Hospital, School of Medicine, Zhejiang University, China.
Informed consent was obtained from all patients before tissue
collection. Decidual tissue was obtained from 25 women aged 21–
36 years (gestational age 5–7 weeks) who had undergone first-
trimester surgical termination of pregnancy. All subjects had an
ultrasound scan to confirm a viable intrauterine pregnancy and
gestational age. None of them had received any hormone or
immunosuppressant treatment for the previous three months.
Preparation of uNK cells
Decidual cells were isolated from tissue as previously described
[22]. Briefly, decidual samples were finely minced into approxi-
mately 1–3 mm
3-size pieces and digested with collagenase type I
(0.1%, Gibco BRL, Gaithersburg, MD, USA) and DNase I
(0.01%, Applichem, Darmstadt, Germany). The cellular superna-
tant was consecutively filtered through 100- and 40-mm mesh
screens. The cells that passed through the mesh screens were
collected, resuspended and plated in phenol red-free RPMI-1640
medium supplemented with 10% charcoal-stripped fetal bovine
serum (FBS; Gibco BRL), 100 IU/mL penicillin (Sigma, St. Louis,
MO, USA), 100 mg/mL streptomycin (Sigma) and 1% L-
glutamine (Gibco BRL). The supernatant containing decidual
lymphocytes was collected. Decidual mononuclear cells were
isolated by density-gradient centrifugation using Ficoll-Paque
PLUS (Shanghai Chemical Reagent Factory, Shanghai, China)
according to the manufacturer’s instructions. Mononuclear cells
were recovered from the interface and washed twice in phosphate-
buffered saline (PBS). Uterine NK cells were purified with a
human NK cell isolation kit (Miltenyi Biotec, Camberley, UK) and
an AutoMACS instrument (Miltenyi Biotec). Cell viability was
consistently $95% as tested by trypan blue exclusion. Isolated
cells underwent suspension culture in phenol red-free RPMI-1640
medium (Gibco BRL) containing 10% charcoal-stripped FBS
(Gibco BRL), 100 IU/mL penicillin (Sigma), 100 mg/mL strepto-
mycin (Sigma), 1% L-glutamine (Gibco BRL), and 200 IU/mL
recombinant human interleukin (IL)-2 (Primegen Bio-Tech,
Shanghai, China).
Flow cytometry
To confirm the purity of isolated uNK cells, the cells were
washed with PBS and incubated with phycoerythrin (PE)-cyanine
5 (Cy5), PE, and fluorescein isothiocyanate (FITC)-conjugated
monoclonal antibodies against CD3, CD56, CD16 or the relevant
isotype control (eBioscience, San Diego, CA, USA) in the dark at
4uC for 30 min. For intracellular perforin analysis, the cells were
collected, fixed with 2% paraformaldehyde, permeabilized with
0.1% Triton X-100, and then stained intracellularly with FITC-
conjugated antibodies for perforin or the isotype control
(eBioscience). Analyses were then conducted on a Beckman-
Coulter Epics Altra Flow cytometer (Beckman-Coulter, Fullerton,
CA, USA). Purity of isolated cells was confirmed to be .95% in
each experiment, as shown previously [22].
Cytotoxicity assay
Uterine NK cell-mediated cytotoxicity was evaluated with the
MTS assay using the NK cell-sensitive cell line K562 (American
Type Culture Collection, Manassas, VA, USA) as the target
[23,24]. The purified uNK cells were cultured in culture medium
for 24 h in a 96-well U-bottom plate (BD Biosciences, Franklin
Lakes, NJ, USA) in the absence or presence of different
concentrations of progesterone (0.01, 0.10, 1, and 10 mM;
Sigma-Aldrich), cortisol (0.01, 0.10, 1, and 10 mM; Sigma-
Aldrich), or mifepristone (0.065, 0.2, and 1 mM; Sigma-Aldrich).
To investigate whether mifepristone affects uNK cell-mediated
cytotoxicity by acting as a glucocorticoid antagonist, we incubated
purified uNK cells with or without 1.0 mM cortisol in the presence
or absence of 1.0 mM mifepristone for 24 h. Cells were then
incubated with K562 cells for 4 h at an effector:target cell ratio of
10:1. Following co-culture, the viability of the target K562 cells
was determined by the MTS assay according to the manufactur-
Figure 1. Analysis of uNK cell-mediated cytotoxicity to target
cells (K562) using the MTS assay. Uterine NK cells were treated with
different concentrations of progesterone or cortisol for 24 h, then uNK
cell-mediated cytotoxicity was evaluated by the MTS assay using the NK
cell-sensitive cell line K562.
doi:10.1371/journal.pone.0036413.g001
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[12(experimental group OD2effector cell OD)/target cell
OD]6100% [25,26], where OD is the optical density.
Western blot
Because NK cells usually die within 24 h when cultured in vitro,
uNK cells were isolated and cultured in the medium without IL-2
for 12 h as a negative control for MAPK/ERK activation. IL-15,
known as a strong stimulator of NK cells, was added and used as a
positive control for MAPK/ERK activation [27–29]. Uterine NK
cells were lysed using protein lysis buffer (2% sodium dodecyl
sulfate [SDS], 20% glycerol, 60 mM Tris-HCl) containing
protease inhibitor. The cell lysates were centrifuged at 10,0006g
for 10 min to remove cell debris. The supernatants were collected
and denatured at 95uC for 10 min in 16 SDS loading buffer.
Protein samples were diluted in 66loading sample buffer (50 mM
Tris-HCl, 100 mM dithiothreitol, 2% SDS [w/v], 10% glycerol
[v/v] and a trace mount of bromophenol), resolved using 10%
SDS-PAGE, and then transferred onto nitrocellulose membranes
(Amersham Bioscience, Piscataway, NJ, USA). Membranes were
blocked in 5% fat-free milk for 1 h and then incubated overnight
at 4uC with primary antibodies against extracellular-signal-
regulated kinase (ERK), phosphorylated (p)-ERK, p38 MAPK
(p38), p-p38, c-Jun N-terminal kinase (JNK), and p-JNK (Cell
Signaling, Danvers, MA, USA). The following day, membranes
were washed (63, for 10 min each) in PBS containing 0.1%
Tween 20 and then incubated for 1 h with the corresponding
secondary antibodies at room temperature. Proteins were detected
with an enhanced chemiluminescence reagent (Amersham Biosci-
ence). Density of the protein bands was measured using Quantity
One software (Bio-Rad, Hercules, CA, USA).
Data analysis
All results were expressed as means 6 SEM. Before statistical
analysis, the data were tested for normal distribution by applying
the one-sample Kolmogorov-Smirnov test. Homogeneity of
variances was evaluated by Levene’s test. Statistical comparisons
were performed by one-way ANOVA followed by a least
significant difference test. A P-value,0.05 was considered
significant. Statistical analyses were performed using SPSS
software, version 16.0 (SPSS, Chicago, IL, USA).
Figure 2. Analysis of uNK-cell cytotoxicity and perforin expression after treatment with different concentrations of mifepristone.
The purified uNK cells were incubated with 0, 65, 200, and 1000 nmol/L mifepristone for 24 h. Then, they were subjected to analysis of uNK-cell
cytotoxicity and perforin expression. A, a representative flow cytometry profiles of perforin expression was shown. Uterine NK-cell cytotoxicity (B) and
perforin (C) expression after treatment with different concentrations of mifepristone were evaluated. Values are expressed as means 6 SEM. The
influence of mifepristone was evaluated by 4 independent experiments. P-values referred to One-way analysis of variance, n=6, * P,0.05 vs. control
group.
doi:10.1371/journal.pone.0036413.g002
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Cortisol increases uNK cell-mediated cytotoxicity but not
progesterone
Human uNK cells were isolated by immunomagnetic separa-
tion and treated with different concentrations of progesterone or
cortisol. As shown in Figure 1, treatment with progesterone from 0
(control) to 10.0 mM did not change uNK cell-mediated
cytotoxicity towards K562 cells. In contrast, concentrations of
cortisol $1.0 mM caused a significant decrease in the effective
cytotoxicity of uNK cells. While the uNK cell-mediated cytotox-
icity without cortisol was 62.362.7%, extents of cytotoxicity after
cortisol treatments were 56.263.1% and 55.164.0% at doses of
1 mM and 10 mM, respectively (P,0.05 for both).
Mifepristone increases uNK cell-mediated cytotoxicity, an
effect reversed by cortisol
It has been reported that when mifepristone was administered at
a dose of 1 mg/day, endometrial development appeared to be
slightly retarded and the steady plasma level of mifepristone was
found to be 65 nmol/L. When the serum mifepristone concen-
tration reached 232.7 nmol/L, ovulation was inhibited.
1000 nmol/L is the steady plasma level of mifepristone with
10 mg/day that achieved the purpose of emergency contraception
[30]. We found that, 65 and 200 nmol/L mifepristone had no
significant influence on human uNK-cell cytotoxicity in vitro.
Compared with control group, human uNK-cell cytotoxicity
(73.1664.27% vs. 62.2464.39%, P,0.05) (Fig. 2B) significantly
increased in 1000 nmol/L (1.0 mM) mifepristone group.
Uterine NK cells were then treated without or with mifepristone
(1.0 mM) in the presence or absence of 1.0 mM cortisol.
Mifepristone without cortisol increased uNK cell-mediated
cytotoxicity (62.362.7% vs. 73.264.3%, P,0.05) and this effect
was reversed by cortisol (73.264.3% vs. 66.962.9%, P,0.05;
Fig. 3B).
Figure 3. Effects of cortisol on mifepristone-induced uNK-cell cytotoxicity and perforin expression. Isolated uNK cells were treated with
cortisol (1.0 mM) 6 and mifepristone (1.0 mM) for 24 h. A, a representative flow cytometry result for perforin expression in different groups. B, results
of uNK-cell cytotoxicity in different groups. C, data summary of flow cytometry results for perforin expression. The value is the percent of perforin-
positive cells in the total number of uNK cells. Experiments were independently repeated 5 independent experiments. Data were analyzed using
ANOVA and expressed as means 6 SEM. *, P,0.05.
doi:10.1371/journal.pone.0036413.g003
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uNK cells is reversed by cortisol
We found that, 65 and 200 nmol/L mifepristone had no
significant influence on human uNK-cell perforin expression in
vitro. Compared with control group, human uNK-cell perforin
expression (49.1362.92% vs. 36.2360.85%, P,0.05) (Fig. 2C)
significantly increased in 1000 nmol/L (1.0 mM) mifepristone
group.
We then explored the effects of cortisol on changes in perforin
expression induced by mifepristone in uNK cells. Cortisol
(1.0 mM) significantly inhibited the mifepristone-induced increase
in perforin expression (36.264.9% vs. 28.562.3%, P,0.05) and
mifepristone significantly increased perforin expression
(36.264.9% vs. 49.162.9%, P,0.05). When uNK cells were
treated with mifepristone (1.0 mM) in the presence of cortisol, the
upregulation of perforin expression by mifepristone in uNK cells
was suppressed (49.162.9% vs. 33.163.5%, P,0.05; Fig. 3C).
Mifepristone increases MAPK/ERK activation in uNK cells
To confirm whether or not the MAPK pathway is involved in
immune regulation by mifepristone, the expression and activation
of ERK, p38 and JNK in uNK cells were determined by Western
blot. Uterine NK cells were treated with 1.0 mM mifepristone for
different times. The results indicated that mifepristone induced a
time-dependent activation of the ERK pathway. Activation of
ERK in uNK cells occurred at 15 min after mifepristone
stimulation, peaked at 30 min, and decreased at 60 and 120 min
(Fig. 4). In contrast, the phosphorylation levels of p38 and JNK in
uNK cells were not altered at the different time points after
mifepristone stimulation. Furthermore, 1.0 mM mifepristone
significantly increased ERK activation at 30 min after the
stimulation (P,0.05) and 1.0 mM cortisol significantly inhibited
ERK activation (P,0.05). When uNK cells were simultaneously
treated with cortisol and mifepristone, activation of the ERK
pathway by mifepristone was suppressed (P,0.05, Fig. 5).
Figure 4. Effects of mifepristone on the phosphorylation level of MAPK in uNK cells. A, a representative immunoblot is shown after the
treatment of uNK cells with mifepristone (1.0 mM) for 0, 15, 30, 60, and 120 min. Uterine NK cells were isolated and cultured in the medium without IL-
2 for 12 h as a negative control of MAPK/ERK activation. In the drug treatment group, uNK cells were cultured in the medium supplemented with IL-2.
Uterine NK cells were cultured in the medium with IL-2 and IL-15 for 15 min as a positive control. Immunodetection of MAPK members used specific
antibodies for phosphorylated and total proteins of ERK1/2, P38 and JNK. B, densitometric scans of triplicate blots are shown. Experiments were
independently repeated 3 times in each group. Data were analyzed using ANOVA and expressed as means 6 SEM. *, P,0.05.
doi:10.1371/journal.pone.0036413.g004
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and perforin expression by activation of the ERK pathway
Because mifepristone appeared to increase ERK activation, we
further investigated the possible role of the ERK pathway in
mifepristone-induced cytotoxicity and changes in perforin expres-
sion in uNK cells. Uterine NK cells were pretreated for 30 min
with either of two specific ERK1/2 inhibitors, PD98059 or
U0126. They were then treated with mifepristone with or without
cortisol for 24 h. The effect of mifepristone 6 cortisol on uNK
cell-mediated cytotoxicity was determined by the MTS assay.
After pretreatment with PD98059 or U0126, mifepristone had no
effect on uNK cell-mediated cytotoxicity, with or without cortisol
(P.0.05, Fig. 6). No changes in perforin expression, due to cortisol
or mifepristone, were observed when uNK cells were pretreated
with PD98059 or U0126 (Fig. 7).
Discussion
Accumulating evidence supports a requirement for optimal
postovulatory increases of uNK cell numbers for successful embryo
implantation and placentation [31,32]. Altered numbers of uNK
cells and their function may be responsible for reproductive
disorders [11]. Our previous research confirmed that low-dose
mifepristone increases the number of CD56
+-NK cells and the
percentages of the NK cell subset CD3
2CD56
+ CD16
2 in human
endometrial explants [13]. Mifepristone can also directly augment
uNK cell-mediated cytotoxicity through the increased expression
of perforin (unpublished result). However, the specific mechanisms
responsible for the effects due to mifepristone in uNK cells are
unclear.
Changes in the production of steroids play a major role in
modulation of local immunosuppression at the maternal-fetal
interface. The number of uNK cells within the endometrial stroma
varies during the menstrual cycle and throughout pregnancy. It is
tempting to speculate that progesterone may be involved in the
ever-changing status of uNK cells. In the present study, however,
we found that progesterone at different concentrations does not
affect uNK cell-mediated cytotoxicity.
Despite expression of the classical PR in peripheral blood NK
cells, strong evidence indicates that neither isoform of the PR is
expressed in uNK cells [17]. The proliferation, target cell lysis and
cytokine secretion of high-purity uNK cells was not influenced by
progesterone in vitro [18]. The current results are consistent with
previous studies and support the concept that progesterone has no
direct effect on the biological activity of uNK cells.
We found that mifepristone augments the cytotoxicity of uNK
cells in culture, and this effect was blocked by cortisol but not
progesterone. This suggested that mifepristone could regulate
uNK cell-mediated cytotoxicity by antagonizing the GR rather
than the PR. Accumulating evidence indicates that mifepristone
has a variety of putative effects on cancer cells and immune cells
[1–5], with the mechanism of action involving antagonism of
hormone receptors [33,34]. Binding of mifepristone to the
receptor induces the loss of associated heat shock proteins and
Figure 5. Effects of mifepristone on the ERK signaling pathway in uNK cells. Western blot of p-ERK and total ERK in uNK cells treated with
mifepristone 6 cortisol. To detect p-ERK and total ERK, total cell lysates were harvested after a 30 min treatment with mifepristone (1.0 mM) 6
cortisol (1.0 mM). Uterine NK cells were isolated and cultured in the medium without IL-2 for 12 h as a negative control of MAPK/ERK activation. In the
drug treatment groups, uNK cells were cultured in the medium supplemented with IL-2. Uterine NK cells were cultured in the medium with IL-2 and
IL-15 for 15 min as a positive control. A typical blot (A) and densitometric scans of triplicate blots (B) are shown. Data were analyzed using ANOVA
and expressed as means 6 SEM. *, P,0.05.
doi:10.1371/journal.pone.0036413.g005
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also binds to hormone response elements and activates some genes
as a partial glucocorticoid agonist if glucocorticoid is absent. When
both glucocorticoids and mifepristone are present, the mifepris-
tone-receptor dimer is transcriptionally inactive as an antagonist of
glucocorticoids [35].
Mifepristone binds to the human GR with an affinity 18 times
greater than that of cortisol [36]. Because mifepristone blocks the
GR in a competitive manner, the effect can be reversed by
glucocorticoid administration [37]. The GR, but not the PR, was
identified in human uNK cells [17]. Therefore, it is reasonable
that the increased cytotoxicity of uNK cells induced by
mifepristone is mediated by action at the GR. In addition, the
opposite effects due to mifepristone and cortisol on uNK cell-
mediated cytotoxicity and perforin expression in the present study
indicated that mifepristone acts as an antagonist rather than
agonist.
NK cells are important for early host defense against infection
and tumors [38,39]. They exert cytotoxic effects primarily through
granule exocytosis [40,41]. Perforin is a cytolytic mediator that is
released by cytoplasmic granules and promotes the death of target
cells [42]. Upon release into the immunologic synapse, perforin
induces lysis of target cells [43]. Through polymerization and
insertion into target cells, perforin causes osmotic leakage and
provides access to other toxic granules, which results in lysis and
apoptosis of the target cells [44]. NK cell-mediated cytolysis is
Figure 6. The increased cytotoxicity of uNK cells by mifepristone was inhibited by PD98059 or U0126. Before the treatment with
cortisol 6 mifepristone, uNK cells were pretreated with PD98059 (A) or U0126 (B) for 30 min. They were then treated with mifepristone 6 cortisol for
24 h. Cells stimulated with IL-15 were used as positive control. The cytotoxicity of uNK cells was detected by the MTS assay. Data were analyzed using
ANOVA and expressed as means 6 SEM. *, P,0.05.
doi:10.1371/journal.pone.0036413.g006
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mobilization and redistribution of perforin play an important role
in the control of NK cytotoxicity [46]. In a previous study, we
showed that in human endometrial explants, mifepristone
increased expression of perforin and increased uNK cell-mediated
cytotoxicity [14]. In the current study, we observed that the
mifepristone-induced increase in perforin expression in uNK cells
can be reversed by cortisol, which indicated that mifepristone
could increase the expression of perforin through the GR.
Glucocorticoids are known to show an immunosuppressive
effect in lymphocytes. In the clinic, glucocorticoids work as
immunosuppressive drugs to impair NK-cell function by affecting
Figure 7. Upregulation of perforin expression by mifepristone was inhibited by PD98059 or U0126. Before the treatment with cortisol
6 mifepristone, uNK cells were pretreated with PD98059 (A) or U0126 (B) for 30 min. They were then treated with mifepristone 6 cortisol for 24 h.
Cells stimulated with IL-15 were used as positive control. Perforin expression in uNK cells was examined by flow cytometry. The value is the percent of
perforin-positive cells in the total number of uNK cells. Data were analyzed using ANOVA and expressed as means 6 SEM. *, P,0.05.
doi:10.1371/journal.pone.0036413.g007
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showed that the suppression of human lymphocyte proliferation by
cortisol can be reversed by mifepristone; however, the suppression
by progesterone is not affected [8].
In the present study, we found that activation of the ERK
pathway by mifepristone was blocked by the presence of cortisol.
This suggests that mifepristone can promote activation of the ERK
pathway through the GR. Moreover, we found that when ERK
activation was inhibited by PD98059 or U0126, neither uNK cell-
mediated cytotoxicity nor perforin expression was influenced by
either cortisol or mifepristone. This implied that the activation of
ERK by mifepristone was involved in the regulation of uNK cell-
mediated cytotoxicity. Usually, the MAPK signaling pathway is
activated through membrane receptors. Although GR is a member
of the nuclear hormone receptor superfamily, it has been shown
that glucocorticoids induce the expression of the glucocorticoid-
leucine zipper (GILZ) and MAPK phosphatase-1 (MKP-1). The
induction of GILZ and MKP-1 genes provides a mechanism by
which GR can modulate the MAPK pathway [48].
NK cell function is controlled by signals generated from
inhibitory and stimulatory receptors. Ligation of the stimulatory
receptor leads to activation of a cascade of intracellular signaling
events, resulting in exocytosis of granules to lyse target cells
[49,50]. Many receptor signaling molecules, including NKG2D
(the best-characterized activating receptor of NK cells), are located
upstream of the MAPK pathway and are involved in controlling
perforin and granzyme B release from NK cells [46,51–53]. It has
also been demonstrated that both the ERK and JNK MAPK
pathways are involved in NKG2D-mediated cytotoxicity [51]. In
addition, glucocorticoids can trigger their biological functions
through the MAPK pathway [54–56]. Because mifepristone is an
antagonist of glucocorticoids, it was expected that the same
pathway would be involved in the regulation of uNK cell-mediated
cytotoxicity by mifepristone.
Our findings indicate that mifepristone may act as a
glucocorticoid antagonist to augment uNK cell-mediated cytotox-
icity through the ERK pathway. We suggest this as a possible
mechanism by which mifepristone contributes to the increased
cytotoxicity of uNK cells, which plays an important role in
endometrial contraception. In conclusion, our findings indicate
that mifepristone may play a pivotal role in the control of
inflammatory responses and suggest a new clinical application for
mifepristone.
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